Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P78363
UPID:
ABCA4_HUMAN
Alternative names:
ATP-binding cassette sub-family A member 4; RIM ABC transporter; Retinal-specific ATP-binding cassette transporter; Stargardt disease protein
Alternative UPACC:
P78363; O15112; O60438; O60915; Q0QD48; Q4LE31
Background:
The Retinal-specific phospholipid-transporting ATPase ABCA4 plays a crucial role in visual processes, catalyzing the ATP-dependent transport of retinal-phosphatidylethanolamine conjugates. This action is vital for converting visual signals into neural signals, a process essential for sight. Known also as Stargardt disease protein, its malfunction is linked to several retinal diseases.
Therapeutic significance:
ABCA4's involvement in diseases like Stargardt disease 1, Fundus flavimaculatus, and age-related Macular degeneration, highlights its therapeutic potential. Targeting ABCA4 could lead to breakthrough treatments for these conditions, offering hope for patients suffering from vision loss.